Milestone Scientific

Milestone Scientific, Inc. is a biomedical technology research and development company, which patents, designs, and develops diagnostic and therapeutic injection technologies and instruments. It operates through the following segments: Dental, Medical, and Corporate. The Corporate segment refers to executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities, and public company compliance costs. Its solutions include CompuFlo Epidural, CathCheck Verification System, and Single Tooth Anesthesia System. The company was founded on August 17, 1989 and is headquartered in Roseland, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Milestone Scientific reports Q1 revenue, eyes international expansion opportunities

Milestone Scientific's Q1 2024 performance showed revenue over $2.2 million with improved gross margins.
The company's focus on customer relationships and reimbursement strategies is a key strength.
Challenges include revenue decrease and the need for endorsements in the medical space.
Opportunities lie in international expansion, market penetration goals, and increased marketing efforts.

Milestone Scientific reports improved Q2 performance amidst revenue challenges

Milestone Scientific showcased financial improvements in Q2 2024 despite a revenue decrease, with a focus on enhancing operational efficiency and achieving positive cash flow.
The company's strategic partnerships, international expansion plans, and commitment to innovation through intellectual property enhancements signal a path for future growth and market competitiveness.
While facing challenges in revenue generation and operational clarity, Milestone Scientific's strong balance sheet and market positioning offer opportunities for sustained growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Milestone Scientific Inc. (NYSE:MLSS ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants David Waldman - IR Jan Haverhals - CEO Keisha Harcum - Controller Conference Call Participants Jeremy Pearlman - Maxim Group Operator Greetings, and welcome to Milestone Scientific's Third Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants have been placed in a listen-only mode, and the floor will be opened for questions following the presentation.

Milestone Scientific Inc. (MLSS) Q3 2023 Earnings Call Transcript

Reports 45% increase in domestic sales for the third quarter of 2023; new online store providing greater interaction with dentists and improved margins

Milestone Scientific Achieves Revenue of $2.1 Million and Provides Business Update for the Third Quarter of 2023

ROSELAND, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Wednesday, November 15, 2023, to discuss the company's financial results for the third quarter ended September 30, 2023, as well as the company's corporate progress and other developments.

Milestone Scientific Schedules Third Quarter 2023 Financial Results and Business Update Conference Call

Represents first sales by the Company into an ambulatory surgery center Follows successful evaluation by Island Ambulatory Surgery Center's founder and medical director, Dr. Leon Reyfman, reporting 100% success ROSELAND, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into Island Ambulatory Surgery Center, a multi-specialty ambulatory surgery center based in Brooklyn, New York with a focus on pain management, orthopedics and spine care, urology, podiatry and plastic surgery.

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Island Ambulatory Surgery Center in Brooklyn, New York

ROSELAND, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dr. Didier Demesmin, MD, MBA, to the Board of Directors.

Milestone Scientific Appoints Pain Management Industry Veteran Dr. Didier Demesmin to its Board of Directors

Milestone Scientific Inc. (NYSE:MLSS ) Q2 2023 Earnings Conference Call August 15, 2023 8:30 AM ET Company Participants David Waldman - Investor Relations Arjan Haverhals - Chief Executive Officer Peter Milligan - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Tucker Andersen - Above All Advisors Operator Greetings, and welcome to the Milestone Scientific Second Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Milestone Scientific Inc. (MLSS) Q2 2023 Earnings Call Transcript

Gross profit increases 178% compared to the same period last year New online store providing greater interaction with dentists and improved margins Medical division reports positive reimbursement from first commercial payers ROSELAND, N.J., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the second quarter ended June 30, 2023.

Milestone Scientific Achieves 77% Year-Over-Year Increase in Revenue to $2.9 Million for the Second Quarter of 2023

ROSELAND, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Tuesday, August 15, 2023, to discuss the company's financial results for the second quarter ended June 30, 2023, as well as the company's corporate progress and other developments.

Milestone Scientific Schedules Second Quarter 2023 Financial Results and Business Update Conference Call

ROSELAND, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery systems that provide painless and precise injections, today announces, positive reimbursement was received from three commercial payers for the use of the CompuFlo® Epidural System for patients who were involved in motor vehicle accidents.

Milestone Scientific Announces Positive Insurance Payment for the CompuFlo® Epidural System

Milestone Scientific offers an innovative product line in the medical and dental segments, including a trademarked solution for Dentists to administer local anesthesia called SingleTooth Anesthesia. The company meets key investment criteria such as a large total addressable market, low institutional ownership, and high Quant ratings. Despite the high level of risk associated with micro caps, I recommend building a small position in the stock for risk-tolerant investors due to its significant upside potential.

Milestone Scientific: Buy For The $4 Billion Total Addressable Market

ROSELAND, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery systems that provide painless and precise injections, today announced that Arjan Haverhals, CEO of Milestone Scientific will be presenting at the Maxim Group Virtual Healthcare Conference, hosted by M-Vest, which is being held June 20-22, 2023.

Milestone Scientific to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20th

The shift to online sales in their dental business produced unexpectedly fast results with revenue and gross margin up sharply and more to come. Most if not all of the pieces necessary for CompuFlo sales to take off are now in place, sales could start to snowball this year. In years to come, CompuFlo could even become the standard of care.

Milestone Scientific: Sales Could Start To Snowball

Follows successful evaluation by Dr. Fabian Proano, MD including complex thoracic procedures Follows successful evaluation by Dr. Fabian Proano, MD including complex thoracic procedures

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within The Pain and Rehabilitation Medical Group in Torrance, California

Milestone Scientific Inc. (NYSE:MLSS ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants David Waldman – Investor Relations Arjan Haverhals – Chief Executive Officer Peter Milligan – Chief Financial Officer Conference Call Participants Anthony Vendetti – Maxim Group Operator Good morning, everyone. And welcome to Milestone Scientific's First Quarter 2023 Financial Results and Business Update Conference Call.

Milestone Scientific Inc. (MLSS) Q1 2023 Earnings Call Transcript

ROSELAND, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the first quarter ended March 31, 2023.

Milestone Scientific Achieves Revenue of $2.6 Million and Provides Business Update for the First Quarter of 2023

ROSELAND, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, as well as AI-assisted medical technology, today announced the successful completion of the first series of epidural steroid injections (ESI) using the CompuFlo Epidural System by physicians under the new American Medical Association (AMA) Current Procedural Terminology (CPT®) guidelines for AI-assisted analgesic epidural needle placement in patients.

Milestone Scientific Announces Successful Epidural Steroid Injection Procedures Under New AMA CPT Guidelines for Artificial Intelligence (AI) Assisted Pain Management Surgery

Follows successful evaluation by Dr. Jimmy D. Huebert, MD, including Epidural Steroid Injection (ESI) procedures in lumbar, thoracic and cervical thoracic junction of the spine Follows successful evaluation by Dr. Jimmy D. Huebert, MD, including Epidural Steroid Injection (ESI) procedures in lumbar, thoracic and cervical thoracic junction of the spine

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within the Sports and Spine Clinic in Oregon

ROSELAND, N.J., May 05, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Thursday, May 11, 2023, to discuss the company's financial results for the first quarter ended March 31, 2023, as well as the company's corporate progress and other developments.

Milestone Scientific Schedules First Quarter 2023 Financial Results and Business Update Conference Call

Milestone Scientific Inc. (NYSE:MLSS ) Q4 2022 Results Conference Call March 31, 2023 8:30 AM ET Company Participants David Waldman - Investor Relations Arjan Haverhals - Chief Executive Officer Peter Milligan - Chief Financial Officer of Milestone Scientifi Conference Call Participants Anthony Vendetti - Maxim Group Mike Pfeffer - Oppenheimer Operator Greetings. Welcome to the Milestone Scientific 2022 Year-end Financial Results and Business Update Conference Call.

Milestone Scientific Inc. (MLSS) Q4 2022 Earnings Call Transcript

ROSELAND, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ending December 31, 2022.

Milestone Scientific Provides 2022 Year-End Business Update

ROSELAND, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, March 31, 2023, to discuss the company's financial results for 2022, as well as the company's corporate progress and other developments.

Milestone Scientific Schedules 2022 Year-End Financial Results and Business Update Conference Call

Follows successful evaluation by its Medical Director and Founder, Dr. Didier Demesmin, MD, MBA Follows successful evaluation by its Medical Director and Founder, Dr. Didier Demesmin, MD, MBA

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within the University Pain and Spine Center which Operates 7 Locations Across New Jersey and New York

Follows successful evaluation by Dr. Brad Sisson, MD, including complex thoracic procedures Follows successful evaluation by Dr. Brad Sisson, MD, including complex thoracic procedures

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Three Prominent Colorado Pain Management Clinics

SAM approval marks an important step in gaining entrée to the Department of Defense, Veterans Affairs and other government agencies SAM approval marks an important step in gaining entrée to the Department of Defense, Veterans Affairs and other government agencies

Milestone Scientific Granted U.S. Government's System for Award Management (SAM) Registration of its CompuFlo® Epidural System

ROSELAND, NJ., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provides painless and precise injections, today announced that its CompuFlo® Epidural System has received 510(k) FDA clearance for use in the thoracic region of the spine, including the cervical thoracic junction. This approval expands upon the Company's prior approval of CompuFlo for use within the lumbar region of the spine, where the focus has been on labor and delivery.

News for Milestone Scientific Stock (MLSS)